Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | NAAA | Q02083 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.30 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.30 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2291119 | 0.90 | GAA (0.33) | PCSK9ALDH1A1NR1H2NR1H3 | |
| SCHEMBL3482551 | 0.84 | PCSK9 (0.39) | PCSK9EGFRNAAAARPTGS2 | |
| SCHEMBL2292460 | 0.82 | NR1H2 (0.33) | TSHRALDH1A1NR1H2NR1H3 | |
| SCHEMBL15302725 | 0.82 | ALDH1A1 (0.34) | LMNATSHRHTTALDH1A1NR1H2 | |
| SCHEMBL273717 | 0.80 | PCSK9 (0.37) | PCSK9EGFRNAAAARPTGS2 | |
| SCHEMBL3481932 | 0.80 | PCSK9 (0.37) | PCSK9EGFRNAAAARPTGS2 | |
| SCHEMBL5077495 | 0.79 | AR (0.37) | PCSK9NAAAARPTGS2TSHR | |
| SCHEMBL6965430 | 0.78 | NAAA (0.41) | PCSK9EGFRNAAAPTGS2HTT | |
| SCHEMBL27827259 | 0.77 | PCSK9 (0.35) | PCSK9EGFRNAAAARPTGS2 | |
| SCHEMBL11780094 | 0.77 | NAAA (0.43) | EGFRNAAAHTTALDH1A1CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268489-B2 | Non-aqueous electrolyte solution for lithium secondary battery and lithium secondary battery comprising the same | LG CHEM, LTD. (KR) | 2012-09-18 | — | — | US | claimed |
| US-20110206999-A1 | NON-AQUEOUS ELECTROLYTE SOLUTION FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY COMPRISING THE SAME | LG CHEM, LTD. (KR) | 2011-08-25 | — | — | US | claimed |
| US-8791221-B2 | Addition-curable metallosiloxane compound | DAICEL CORPORATION (JP) | 2014-07-29 | — | — | US | disclosed |
| EP-2650319-A1 | ADDITION-CURABLE METALLOSILOXANE COMPOUND | Daicel Corporation (JP) | 2013-10-16 | — | — | EP | disclosed |
| US-20130267653-A1 | ADDITION-CURABLE METALLOSILOXANE COMPOUND | DAICEL CORPORATION (JP) | 2013-10-10 | — | — | US | disclosed |
| CN-103249762-A | Addition-curable metallosiloxane compound | DAICEL CORP | 2013-08-14 | — | — | CN | disclosed |
| US-8268489-B2 | Non-aqueous electrolyte solution for lithium secondary battery and lithium secondary battery comprising the same | LG CHEM, LTD. (KR) | 2012-09-18 | — | — | US | disclosed |
| US-20110206999-A1 | NON-AQUEOUS ELECTROLYTE SOLUTION FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY COMPRISING THE SAME | LG CHEM, LTD. (KR) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267653-A1 | ADDITION-CURABLE METALLOSILOXANE COMPOUND | B2M, MSI2, MNS1 | PCSK9 4133/4885EGFR 2718/4885NAAA 2244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.